Syantis ki soti nan de konpayi yo te analize sekans Variant SARS-CoV-2 Omicron, chwazi sekans viral yo, ak klon plasmid ki fèt. Nou espere nouvo vaksen Omicron SARS-CoV-2 variant yo ka avanse nan tès klinik nan mwens pase 100 jou.
"Nou kwè li esansyèl pou devlope nouvo vaksen rapid ak efikas pou konbat nouvo variant Omicron COVID-19 la. Nou pral travay kole kole ak kò regilasyon yo epi chèche etid klinik apwopriye ak apwobasyon regilasyon pou pote vaksen sa a sou mache pi vit posib.” di Brad Sorenson, PDG Providence Therapeutics.
"Nou espere devlope rapidman nouvo vaksen Omicron Variant sa a ak Providence, epi pote benefis vaksen sa a nan zòn sa yo ki gen pi ba aksè nan tretman vaksen mRNA aktyèl yo an patikilye." fè kòmantè Kerry Blanchard, MD, PhD, Ofisye Chèf Egzekitif Everest Medicines.
KISA POU RETIRE NAN ATIK SA A:
- “We look forward to rapidly developing this new Omicron variant vaccine with Providence, and bringing the benefit of this vaccine to those areas with lower accessibility to current mRNA vaccine treatments in particular.
- “We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant.
- We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.
